Curis Inc
CUS0
Company Profile
Business description
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Contact
128 Spring Street
Building C - Suite 500
LexingtonMA02421
USAT: +1 617 503-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
33
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.60 | 49.30 | -0.55% |
| CAC 40 | 8,106.16 | 18.72 | -0.23% |
| DAX 40 | 24,076.87 | 153.04 | -0.63% |
| Dow JONES (US) | 48,202.97 | 213.59 | -0.44% |
| FTSE 100 | 9,684.79 | 66.52 | -0.68% |
| HKSE | 25,235.41 | 393.47 | -1.54% |
| NASDAQ | 23,052.15 | 5.26 | -0.02% |
| Nikkei 225 | 49,383.29 | 784.82 | -1.56% |
| NZX 50 Index | 13,424.95 | 16.81 | 0.13% |
| S&P 500 | 6,794.62 | 21.89 | -0.32% |
| S&P/ASX 200 | 8,598.90 | 48.40 | -0.56% |
| SSE Composite Index | 3,824.81 | 43.11 | -1.11% |